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under the CC BY-NC-phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody binding sol-
uble amyloid-b peptide, on cognitive and functional decline over 80 weeks in patients with mild-to-
moderate Alzheimer’s disease (AD). Primary findings for both studies have been published.
Methods: Secondary analyses of efficacy, biomarker, and safety endpoints in the pooled
(EXPEDTION 1 EXPEDITION2) mild AD population were performed.
Results: In the mild AD population, less cognitive and functional decline was observed with solane-
zumab (n 5 659) versus placebo (n 5 663), measured by Alzheimer’s Disease Assessment Scale
Cognitive subscale,Mini-Mental State Examination, andAlzheimer’s Disease Cooperative Study–Ac-
tivities of Daily Living functional scale Instrumental ADLs. Baseline-to-endpoint changes did not
differ between treatment groups forAlzheimer’sDiseaseCooperative Study–Activities ofDaily Living
functional scale, basic items of the ADCS-ADL, and Clinical Dementia Rating Sum of Boxes. Plasma/
cerebrospinal fluid biomarker findings indicated target engagement by solanezumab. Solanezumab
demonstrated acceptable safety. Efficacy findings for the moderate AD population are also provided.
Discussion: These findings describe solanezumab effects on efficacy/safety measures in a mild AD
population. Another phase 3 study, EXPEDITION3, will investigate solanezumab’s effects in a mild
AD population.
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successful thus far. Most of these investigational agents
were intended to target the amyloid-b (Ab) peptide or
deposited amyloid plaques [1], although clear evidence of
target engagement has not been consistently demonstrated
[2]. Biomarker evidence of target engagement has been
demonstrated for semagacestat, a gamma-secretase inhibitor
[3,4] and bapineuzumab, a monoclonal antibody targeting
deposited amyloid plaques [5]. Despite evidence for target
engagement in the central nervous system, in recent phase
3 trials, semagacestat was unexpectedly shown to causeInc. on behalf of the Alzheimer’s Association. This is an open access article
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effect on cognitive decline [5].
Solanezumab is an IgG1 antiamyloid monoclonal anti-
body that binds to the mid-domain of the Ab peptide and
is thought to increase clearance of soluble Ab. Preclinical
studies using transgenic APPV717F mice demonstrated that
administration of the murine anti-Ab monoclonal antibody
from which solanezumab was derived (m266.2) reduced
brain amyloid plaque deposition [6,7] and showed strong
correlations between plasma Ab accumulation and plaque
deposition. In phase 1 and phase 2 studies of patients with
mild-to-moderate AD, evidence of target engagement was
demonstrated by dose-dependent increases in plasma and
cerebrospinal fluid (CSF) total (bound plus unbound) Ab
[8,9]. The increase in CSF total Ab is presumably a result
of solanezumab movement from plasma to the central
nervous system, binding to Ab in that compartment with
accumulation of measureable total Ab in CSF [8].
Solanezumab administration had more complex effects on
free (unbound) isoforms of Ab in CSF. In the phase 2
study of patients with AD, 12 weeks of solanezumab
treatment produced a dose-dependent increase in CSF free
Ab1–42, the predominant form of Ab found in amyloid
plaque. In contrast, solanezumab produced evidence of a
dose-dependent decrease in CSF free Ab1–40, a much less
abundant form of Ab in amyloid plaque [9]. The cause of
these disparate effects on the free fractions of Ab1–42 and
Ab1–40 is not entirely clear. Given that solanezumab has
similar affinity for the two Ab isoforms and the relative
abundance of each isoform is different in amyloid
plaque (consisting primarily of Ab1–42), we questioned
whether solanezumab might be altering equilibria such
that concentrations of free Ab1–42 in CSF might be
different from those of free Ab1–40 after administration of
solanezumab because of the relative abundance of Ab1–42
in plaque [2,9].
The first phase 3 studies of solanezumab (EXPEDITION
and EXPEDITION2) examined the effect versus placebo on
cognitive and functional decline over 80 weeks in patients
with mild-to-moderate AD dementia. The original planned
coprimary endpoints in both studies were the Alzheimer’s
Disease Assessment Scale Cognitive subscale (ADAS-
Cog11) [10,11] and the Alzheimer’s Disease Cooperative
Study–Activities of Daily Living functional scale (ADCS-
ADL) [12]. Primary outcome findings from these two sepa-
rate studies, with analyses conducted by the ADCS Data
Analysis and Publication Committee, have been described
previously [13]. Neither study showed a significant benefit
of solanezumab for both originally designated coprimary
outcomes.
Key prespecified secondary analyses in the EXPEDI-
TION and EXPEDITION2 statistical analysis plans
(SAPs) included subgroup analyses based on disease
severity (mild or moderate AD dementia) at baseline; these
analyses were performed based on the concept that
therapies targeting amyloid should be started early in theAD disease process to substantially modify the course of
the disease [14]. In addition, because EXPEDITION and
EXPEDITION2 were identical in design, an SAP was
developed for a secondary analysis of the pooled data
from these two studies, which included analyses of the
mild and moderate AD populations separately. After re-
view of the analyses of the pooled mild AD population
described in this report, a third phase 3 trial, EXPEDI-
TION3, was initiated to continue to explore the effects of
solanezumab in patients with mild AD.2. Methods
2.1. Study design
The designs of the phase 3 trials, EXPEDITION and
EXPEDITION2, have been described previously [13,15,16].
Briefly, both were multinational, randomized, double-
blind, placebo-controlled studies of solanezumab 400 mg
in outpatients with mild-to-moderate AD. Patients were at
least 55 years old and met criteria for probable AD
based on National Institute of Neurological and
Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Association criteria [17].
Patients with Mini-Mental State Examination (MMSE)
[18] scores of 16 through 26 were allowed to participate.
Mild disease was defined as screening visit MMSE
scores of 20–26; moderate was defined as screening
visit scores of 16–19. Subjects were randomized by
investigative site and AD severity (mild/moderate) to ensure
an even distribution of severity of disease across treatment
groups.
Study medication was given intravenously every 4 weeks
through week 76, with final evaluations occurring 4 weeks
later at week 80, such that total duration was approximately
18 months. Subjects were allowed to continue on stable
doses of standard of care symptomatic medications, such
as acetylcholinesterase inhibitors and memantine, for the
duration of the study.
After obtaining results from EXPEDITION, but before
obtaining results from EXPEDITION2, the SAP for the
pooled data set (EXPEDITION plus EXPEDITION2) was
modified to consider the mild AD population as primary,
with the ADAS-Cog14 as the primary efficacy outcome.
The ADAS-Cog14 is an expanded version of the ADAS-
Cog11 that includes three additional items to assess execu-
tive function and delayed verbal recall; these additional
domains may be more likely to be affected in patients
with mild AD, thereby increasing the sensitivity of the
scale in this population [11].
Other prespecified outcome measures included ADAS-
Cog11, ADCS-ADL (total score and subscores for the basic
and instrumental ADLs), Clinical Dementia Rating Sum of
Boxes (CDR-SB), and MMSE. The ADAS-Cog14, ADAS-
Cog11, and ADCS-ADL were administered at baseline and
weeks 12, 28, 40, 52, 64, and 80; and the CDR-SB and
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and 80.
Plasma Ab1–40 and Ab1–42 levels were measured as
described previously [19] and brain volumetric magnetic
resonance imaging (vMRI) was performed at multiple time
points in all subjects. In those participating in an optional
study addendum, CSF free (unbound) and total (bound
plus unbound) fractions of Ab1–40 and Ab1–42 and CSF tau
and phosphorylated-tau (p-tau) were measured as described
previously [9,19,20]. In a second optional study addendum,
amyloid burden was assessed by a positron emission
tomography (PET) scan using florbetapir F18 [21]. In these
addenda, CSF proteins and amyloid burden were measured
at baseline and week 80 or early termination.
Proprietary, validated, drug-tolerant assays were used to
detect, characterize, and titer treatment-emergent antidrug
antibodies.2.2. Statistical methods
Unless otherwise specified, data were analyzed using the
intent-to-treat mild AD population (i.e., all randomized sub-
jects with mild AD in EXPEDITION and EXPEDITION2),
and all tests of treatment effects were to be conducted at a
two-sidedalpha level of 0.05.Baseline for the treatment period
was defined as the last observation collected before the first
infusion of study medication unless otherwise specified.
Baseline characteristics were summarized by treatment
group and overall for all randomized subjects with mild
AD. The Cochran-Mantel-Haenszel test, controlling for
study, was used for treatment group comparisons of categor-
ical data. For continuous data, analysis of variance, with in-
dependent factors for treatment and investigator, was used.
To test the hypothesis that solanezumab slowed cognitive
decline compared with placebo in patients with mild AD, we
used a mixed model repeated measures (MMRM) analysis
for ADAS-Cog14. An MMRM analysis was used for other
efficacy outcome measures also. A repeated measures anal-
ysis modeling the change from baseline score at each sched-
uled postbaseline visit as the dependent variable was
constructed. The model for the fixed effects included terms
for eight effects: baseline score, study, treatment, study-
by-treatment interaction, visit, treatment-by-visit interac-
tion, concomitant AChEI and/or memantine use at baseline
(yes/no), and age at baseline. Visit was considered a categor-
ical variable with values equal to the visit numbers at which
the scales were assessed. The null hypothesis was that the
difference between solanezumab versus placebo at the last
visit (week 80) equaled zero. To assess the effects of missing
data on our conclusions, sensitivity analyses were conduct-
ed, including selection modeling and pattern mixture
modeling, on the individual study data for the ADAS-
Cog14 and the instrumental items of the ADCS-ADL
(ADCS-iADL).
For assessment of brain amyloid burden, a composite
standardized uptake value ratio (SUVR) was derived thatincluded the anterior and posterior cingulate, frontal cortex,
temporal cortex, parietal cortex, and precuneus regions
normalized to the mean whole cerebellum [22]. Analysis
of change in composite SUVR and the changes in CSF ana-
lytes (Ab1–40, Ab1–42, total tau, and p-tau) were performed
using analysis of covariance models including terms for
baseline, study, treatment, study-by-treatment interaction,
and baseline age.
Because vMRI (whole brain atrophy and total ventricular
volume) and measurement of plasma Ab (Ab1–40 and
Ab1–42) were performed at multiple time points during the
studies, each parameter was analyzed separately using an
MMRM analysis. Change from baseline score at each post-
baseline visit on which the measure was performed was the
dependent variable. The model for the fixed effects included
the following independent terms: baseline value, study, treat-
ment, visit, treatment-by-visit interaction, study-by-
treatment interaction, and age at baseline. Visit was a
categorical variable.
All safety analyses were performed using data from all
randomized subjects with mild AD in EXPEDITION and
EXPEDITION2 who had received at least one dose of
study medication. Treatment-emergent adverse events
(TEAEs) were defined as adverse events (AEs) that first
occurred or worsened on or after baseline. Adverse events
were coded according to established MedDRA terms and
summarized by MedDRA system organ class (SOC) and
preferred term (PT). For TEAEs of special interest (e.g.,
potential class effects and prior and potential signals iden-
tified during safety surveillance), separate analyses were
performed using predefined MedDRA standard medical
queries (SMQs). For cardiac arrhythmia, SMQs used
were arrhythmia-related investigations, signs, and symp-
toms; bradyarrhythmias (including conduction defects and
disorders of sinus node function); cardiac arrhythmia
terms, nonspecific; supraventricular tachyarrhythmias;
tachyarrhythmia terms, nonspecific; and ventricular tachy-
arrhythmias. For cardiac ischemic events, SMQs were
acute myocardial infarction and other ischemic heart dis-
ease. For suicidal ideation or behavior, the SMQ was
suicide/self-injury. For hemorrhagic stroke, the SMQ was
haemorrhagic cerebrovascular conditions. For infusion-
related reactions, the SMQ was anaphylactic reaction;
two additional PTs, infusion-related reaction and urticaria,
were also included. Analyses of TEAE data were per-
formed using a Cochran-Mantel-Haenszel test with study
as strata.
Magnetic resonance imaging (MRI) of the brain was
performed at weeks 0, 12, 28, 52, and 80 (endpoint) or
early discontinuation to evaluate possible amyloid-related
imaging abnormalities-hemosiderin deposition/hemorrhage
(ARIA-H) and/or amyloid-related imaging abnormalities-
edema/effusion (ARIA-E). ARIA-H was quantified cate-
gorically by number of microhemorrhages (0, 1, 2–5, 6–
10, .10). A categorical increase was defined as a shift to
a higher category; any increase in number of
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gorical increase.
All statistical analyses in this report were performed by
Eli Lilly and Company or a contracted research organiza-
tion. The analyses in this report were performed indepen-
dently from those reported previously [13].3. Results
Flow of subjects with mild AD through the EXPEDI-
TION trials is shown in Fig. 1. A total of 1322 patients
with mild AD were randomized in EXPEDITION plus
EXPEDITION2. Of these, 521 of the 663 assigned to
placebo (79%) completed the study, versus 503 of the 659
assigned solanezumab (76%; P . .05).3.1. Baseline characteristics
Baseline demographic and clinical characteristics of the
pooled mild AD population are summarized in Table 1. No
differences between the treatment groups were observed
for age, gender, or race (P . .05). Of note, almost 90% of
the study population was taking a concomitant standard of
care treatment for AD. Except for expected geographic dif-
ferences in standard of care practices, baseline demographic
and outcome measures for the mild AD population appeared
similar in the EXPEDITION and EXPEDITION2 studies
(data not shown).Fig. 1. Flow of study subjects. aDisease severity was based on baseline MMSE
was outside of the study eligibility range (.26) for some randomized subjects,
included in pooled mild-AD data set. Abbreviations: MMSE, Mini-Mental Stat
echocardiogram.3.2. Efficacy findings
In the pooled mild AD population, less decline from base-
line to endpoint was observed in the solanezumab treatment
group versus placebo for the ADAS-Cog14 (primary efficacy
outcome measure for the analyses of the pooled data set), as
well as some other prespecified cognitive and functional out-
comes (ADAS-Cog11, MMSE, and ADCS-iADL; P, .05 in
all cases; Table 2). For the ADAS-Cog14 and MMSE, there
was a slowing of decline of 34%; for ADCS-iADL, there
was a slowing of decline of 18%. The decline from baseline
did not differ between solanezumab and placebo groups in
the case of ADCS-ADL, basic items of the ADCS-ADL
(ADCS-bADL), and CDR-SB. For each measure, the
study-by-treatment interaction was not significant. Sensi-
tivity analyses findings were consistent with these findings
and did not affect the conclusions (data not shown). Findings
for the pooled moderate AD population are provided in
Supplementary Table 1.
Fig. 2 shows the mean change over the course of
18 months of treatment with solanezumab or placebo for
cognitive and functional outcomes. For the ADAS-Cog14,
as well as the ADAS-Cog11, significant differences between
treatment groups (P , .05) were first observed at week 40
and were sustained through endpoint (week 80). For
MMSE, the difference between treatment groups reached
significance at endpoint (P , .001). For the ADCS-iADL,
significant differences between treatment groups (P , .05)
were observed at week 64 and sustained through endpoint.score (mild, MMSE 20–26; moderate, MMSE 16–19). Baseline MMSE
and these individuals were not categorized based on disease severity nor
e Examination; AD, Alzheimer’s disease; lab, laboratory measure; ECG,
Table 1
Baseline characteristics for the mild AD study population
Baseline characteristic Placebo* (n 5 663) Solanezumab* (n 5 659) Total (N 5 1322)
Age, mean (SD), y 73.3 (7.9) 73.9 (8.1) 73.6 (8.0)
Education, mean (SD), y 12.6 (3.9) 12.4 (4.0) 12.5 (4.0)
Female, n (%) 362 (54.6) 346 (52.5) 708 (53.6)
Race, n (%)
White 558 (84.2) 530 (80.4) 1088 (82.3)
Black or African American 12 (1.8) 16 (2.4) 28 (2.1)
Asian 91 (13.7) 111 (16.8) 202 (15.3)
Othery 2 (0.3) 2 (0.3) 4 (0.3)
APOE ε4 carriers, n (%)z 367 (59.8) 329 (55.3) 696 (57.6)
Time since symptom onset, mean (SD), y 4.2 (2.6) 4.3 (2.4) 4.3 (2.5)
Time since diagnosis, mean (SD), y 2.0 (1.9) 1.9 (1.8) 1.9 (1.8)
Standard of Care medication at baseline, n (%) 587 (88.5) 574 (87.1) 1161 (87.8)
Baseline efficacy measures
MMSE 22.5 (2.8) 22.5 (2.8) 22.5 (2.8)
ADAS-Cog11 18.9 (7.0) 19.4 (6.9) 19.1 (6.9)
ADAS-Cog14 29.6 (8.8) 30.1 (8.6) 29.9 (8.7)
ADCS-ADL 63.8 (10.8) 63.4 (11.2) 63.6 (11.0)
ADCS-bADL 20.9 (2.1) 21.0 (1.9) 20.9 (2.0)
ADCS-iADL 42.9 (9.5) 42.4 (10.0) 42.7 (9.7)
CDR-SB 4.4 (2.2) 4.4 (2.1) 4.4 (2.1)
Abbreviations: AD, Alzheimer’s disease; SD, standard deviation; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; ADAS-Cog, Alz-
heimer’s Disease Assessment Scale–Cognitive subscale (11 item and 14 item); ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living
Inventory; ADCS-bADL, ADCS-ADL Basic ADLs; ADCS-iADL, ADCS-ADL Instrumental ADLs; CDR-SB, Clinical Dementia Rating Sum of Boxes.
*Number of randomized subjects. For baseline efficacy measures, the number of subjects included in each analysis varies based on the number of subjects
with a baseline value for that measure.
yOther comprises American Indian or Alaska Native, and Multiple.
zPercentage based on number of subjects with APOE ε4 status available (placebo, 614; solanezumab, 595).
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change from baseline on the ADCS-ADL, the ADCS-
bADL subscale or the CDR-SB (P . .05). The placebo
versus active treatment group differences in the ADAS-
Cog14 and ADCS-iADL increased over 18 months.3.3. Biomarker findings
Plasma levels of both Ab1–40 and Ab1–42 rose between
baseline and the first postbaseline assessment (week 2),
eventually approximating and remaining roughly 300- toTable 2
Mean change (baseline to endpoint) in prespecified outcome measures for the mi
Outcome measurey
Least squares mean change (SE)
Placebo* (n 5 663) Solanezumab* (
ADAS-Cog14 6.21 (0.49) 4.08 (0.50)
ADAS-Cog11 5.00 (0.41) 3.26 (0.42)
MMSE 22.76 (0.22) 21.83 (0.22)
ADCS-ADL 28.55 (0.56) 27.13 (0.57)
ADCS-bADL 21.72 (0.15) 21.48 (0.15)
ADCS-iADL 26.77 (0.46) 25.56 (0.47)
CDR-SB 1.69 (0.13) 1.53 (0.13)
Abbreviations: AD, Alzheimer’s disease; ADAS-Cog, Alzheimer’s Disease As
Mental State Examination; ADCS-ADL, Alzheimer’s Disease Cooperative Stud
ADLs; ADCS-iADL, ADCS-ADL Instrumental ADLs; CDR-SB, Clinical Demen
*Number of randomized subjects. The number of subjects included in each anal
value for that measure.
yWorsening of illness is indicated by increasing score on the ADAS-Cog and C500-fold higher through week 80 in the solanezumab treat-
ment group compared with placebo (P , .001 for both spe-
cies); no increases in Ab1–40 or Ab1–42 were seen in subjects
assigned placebo.
Overall, 185 subjects with mild AD participated in the
optional CSF collection addendum. Baseline to endpoint
change in level of CSF total (bound plus unbound) Ab1–40
was greater in the solanezumab treatment group (least
squares mean change [standard error, SE], 2774.0 pg/mL
[468.2]) versus placebo (2721.8 pg/mL [469.7];
P , .0001), as was change in level of CSF total Ab1–42ld AD study population
P value
Reduction in decline with
solanezumab versus placebo, %n 5 659)
.001 34.3
.001 34.8
.001 33.7
.057 16.6
.24 14.0
.045 17.9
.34 9.5
sessment Scale–Cognitive subscale (11 item and 14 item); MMSE, Mini-
y Activities of Daily Living Inventory; ADCS-bADL, ADCS-ADL Basic
tia Rating Sum of Boxes.
ysis varies based on the number of subjects with a baseline and postbaseline
DR-SB but decreasing score on the MMSE and ADCS-ADL.
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Table 3
Pooled safety findings for the mild AD study population
Event
Number of events (%)
P value
Placebo*
(n 5 660)
Solanezumab*
(n 5 654)
Discontinuations due to AE 58 (8.8) 67 (10.2) .37
Deathsy 8 (1.2) 14 (2.1) .19
Serious SAEsz 132 (20.0) 127 (19.4) .79
Non-cardiac chest pain 4 (0.6) 0 .046
TEAEsz 551 (83.5) 545 (83.3) .94
Cardiac failure congestive 0 4 (0.6) .044
Arthropod stings 0 6 (0.9) .014
Emphysema 0 4 (0.6) .044
Rash pruritic 0 6 (0.9) .014
Rash papular 0 5 (0.8) .024
Cardiac AEs of interest
Cardiac ischemiax 10 (1.5) 15 (2.3) .30
Cardiac arrhythmiax 32 (4.8) 41 (6.3) .26
Abbreviations: AD, Alzheimer’s disease; AE, adverse event; SAE,
serious AE; TEAE, treatment-emergent adverse event.
*Number of randomized subjects who received at least one dose of study
medication.
yDeaths in the placebo treatment group were reported to be due to cardiac
arrest, laryngeal cancer, respiratory arrest, respiratory failure, pneumonia,
renal failure chronic, and subarachnoid hemorrhage. Deaths in the solanezu-
mab treatment group were reported to be due to acute myocardial infarction,
B-cell lymphoma, cardiac arrest, cardiogenic shock, completed suicide,
haemorrhagic stroke, lower respiratory tract infection, myocardial infarc-
tion, pneumonia, respiratory failure, septic shock, and unresponsive to stim-
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concentration of free (unbound) Ab1–40 decreased more in
the solanezumab treatment group (21053.5 pg/mL
[199.1]) than in the placebo group (2314.6 pg/mL
[199.4]; P 5 .01). In contrast, change in CSF level of free
Ab1–42 did not differ between the solanezumab treatment
group (221.4 pg/mL [13.2] vs. placebo 235.6 pg/mL
[13.4]; P 5 .46). Baseline to endpoint changes in levels of
CSF total tau and p-tau did not differ between treatment
groups (P . .05; Supplementary Table 2).
Of the 251 subjects with mild AD who participated in the
optional amyloid imaging addendum and had interpretable
baseline scans, 195 (78%) were considered to have positive
amyloid burden at baseline based on a centralized visual
reading of the PET scans. For these baseline amyloid posi-
tive subjects, the treatment group difference in baseline to
endpoint change in composite summary SUVR normalized
to mean whole cerebellum did not reach statistical signifi-
cance (LS mean change [SE] placebo: 0.02 [0.017] vs. sola-
nezumab: 20.01 [0.019]; P 5 .17).
Baseline to endpoint changes in whole brain and ventric-
ular volume as measured by vMRI did not differ between
treatment groups (P . .05; Supplementary Table 3). In
both the solanezumab and placebo group, the loss in whole
brain volume (atrophy) was approximately 20 cm3 and ven-
tricular size increased approximately 6.7 cm3.uli. All causes are listed at the MedDRA preferred term level.
zSpecific events are shown at the MedDRA preferred term level where
differences between treatment groups at P , .05.
xComprises relevant SMQs (see Methods section for details).3.4. Safety findings
There were no differences between treatment groups in
number of reported deaths (P . .05; Table 3). At the SOC
level, there were no differences between groups in reporting
frequency of serious adverse events (SAEs; P . .05 vs. pla-
cebo) with the exception of cardiac disorders, where events
were more frequently reported in the solanezumab versus
placebo group (3.8% vs. 1.8%; P 5 .028); the incidence of
individual SAEs at the PT level within this SOC was not
significantly different between groups. At the PT level, the
only SAE for which there was a difference in reporting fre-
quency between treatment groups was noncardiac chest pain
which was less frequently reported in the solanezumab treat-
ment group (P 5 .046; Table 3).
Fewer solanezumab- versus placebo-assigned subjects re-
ported TEAEs within the following SOCs: nervous system
disorders (27.8% vs. 33.8%; P 5 .019); injury, poisoning,
and procedural complications (20.8% vs. 25.5%;
P 5 .045); and vascular disorders (8.0% vs. 11.7%;
P 5 .024). There were no SOCs for which TEAEs were
reported more frequently with solanezumab. TEAEs atFig. 2. LS mean change from baseline in (A) ADAS-Cog11, (B) ADAS-Cog14, (C
CDR-SB over the 80-week study period for the mild AD study population. P value
point and for difference between groups at 80 weeks. Error bars represent standar
ations: ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive subscale (1
Alzheimer’s Disease Cooperative StudyActivities of Daily Living Inventory; ADCS
ADLs; CDR-SB, Clinical Dementia Rating Sum of Boxes.the PT level which were reported more frequently
with solanezumab were cardiac failure congestive,
arthropod sting, emphysema, rash pruritic, and rash
papular (Table 3); 14 TEAEs at the PT level (accidental
overdose, hemoglobin decreased, major depression, urinary
incontinence, hematuria, upper respiratory tract infection,
sinusitis, subdural hematoma, procedural pain, lacunar
infarction, duodenal ulcer, helicobacter infection, dermatitis
allergic, and skin neoplasm excision) were reported more
frequently with placebo (P , .05).
Treatment-emergent cardiac-related events from the car-
diac disorders SOC with a treatment group difference at
P , .10 were examined and revealed the following: The re-
ported incidences of individual cardiac events (angina pecto-
ris, sinus bradycardia, cardiac failure congestive, and acute
myocardial infarction) were 1.1% for either treatment
group. Only cardiac failure congestive was reported more
frequently in the solanezumab versus placebo group) MMSE, (D) ADCS-ADL, (E) ADCS-iADLs, (F) ADCS-bADLs, and (G)
s shown where P, .05 for difference between treatment groups at any time
d error. Arrows show direction for cognitive or functional decline. Abbrevi-
1 item and 14 item); MMSE, Mini-Mental State Examination; ADCS-ADL,
-iADL, ADCS-ADL Instrumental ADLs; ADCS-bADL, ADCS-ADLBasic
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ischemic events nor of cardiac arrhythmias differed between
treatment groups (P . .05; Table 3).
Neither the overall incidences of events categorized as
treatment-emergent infusion-related reactions, suicidal idea-
tion or behavior, or hemorrhagic stroke, nor the incidences
of any individual events at the PT level within the relevant
SMQs differed between treatment groups (P . .05 in all
cases).
There were no differences between the treatment groups
in the percentage of subjects with ARIA-E or ARIA-H as
determined by MRI (P . .05). Thirteen subjects (placebo,
four; solanezumab, nine) experienced ARIA-E. Six of the
10 for whom the information was available carried at least
one apolipoprotein E (APOE) ε4 allele. The time-to-
resolution of ARIA-E varied. Of the placebo-assigned sub-
jects who had ARIA-E, two showed complete resolution
and two showed partial resolution during follow-up. For
those assigned solanezumab, five showed complete resolu-
tion, three showed partial resolution, and one showed no
change in ARIA-E severity during follow-up. There were
no clinical symptoms clearly associated with ARIA-E for
any subject. One subject reported headache and nausea dur-
ing the time when ARIA-E was present but this resolved
within 24 hours after paracetamol treatment before the
ARIA-E resolution. At baseline, 248 subjects (19%) had
ARIA-H (placebo, 122; solanezumab, 126). Of these, 132
(53%) had only a single ARIA-H. Overall, there was an in-
crease in size of preexisting ARIA-H and/or increase in
ARIA-H number in 36 subjects in the placebo group
(5.6%) and 40 (6.6%) in the solanezumab treatment group
(P5 .55). Therewas no difference between treatment groups
in the number of categorical increases (P 5 .32).
Treatment-emergent antisolanezumab antibodies were
generally transient, of low titer and did not appear to be asso-
ciated with alteration of drug levels. There were no differ-
ences (P . .05) between treatment groups at any time
point in the frequency of detection of antisolanezumab anti-
body; the number with antidrug antibodies ranged from 1
(0.2%) to 10 (1.9%) in the placebo group and 2 (0.3%) to
5 (0.9%) in the solanezumab group, depending on visit
week. No subjects with treatment-emergent antisolanezu-
mab antibodies experienced TEAEs associated with immune
activation.4. Discussion
While EXPEDITION and EXPEDITION2 did not meet
their primary endpoints, results from the secondary analyses
of this pooled mild AD population showed less worsening in
cognition in those assigned solanezumab versus placebo.
This finding pertained to the ADAS-Cog14 and other cogni-
tive measures (ADAS-Cog11, MMSE). Solanezumab did not
reduce functional decline as assessed using the full ADCS-
ADL; however, using the ADCS-iADL, less functional
decline was seen in the solanezumab treatment group thanplacebo (P 5 .045). As evidenced by the lack of interaction
between study and treatment for these outcome measures,
these effects were generally consistent across the two clin-
ical trials. Solanezumab did not, however, reduce decline
as determined by the CDR-SB, a composite measure assess-
ing both cognition and function. Ratings for this instrument
are determined after a semistructured interview with the
patient and an informant and do not rely directly on psycho-
metric tests. One possible explanation for the lack of treat-
ment separation is that although the CDR-SB has
demonstrated good intrarater reliability (and thus is able to
detect disease progression), inter-rater reliability varies
and intercenter reliability is low (such that the CDR-SB
may not be capable of detecting a treatment effect)
[23,24]. Furthermore, the CDR-SB consists of just six items,
three cognitive and three functional, each of which are rated
categorically; the ADAS-cog14 and ADCS-iADL contain
14 and 18 items, respectively. Nevertheless, the reason(s)
for the lack of effect of solanezumab on the CDR-SB, while
an effect on both the ADAS-cog and ADCS-iADL appeared
to be present, are unclear. The CDR-SB is included in the
ongoing EXPEDITION3 study, which will provide another
opportunity to compare the performance of the CDR-SB to
that of other cognitive and functional measures in a large
global clinical trial.
No evidence of slowing of cognitive or functional decline
with solanezumab was seen in those subjects who had mod-
erate AD at study commencement (Supplementary Table 1).
Although therapies targeting amyloid might be more effica-
cious when started earlier in the disease process [4,14], the
reason for such a marked difference in efficacy in the mild
and moderate AD populations in the EXPEDITION trials
is unclear. Given that progression of AD occurs across a
continuum, although these data suggest that there was a
greater effect of solanezumab in subjects with an MMSE
score of 20–26 at baseline compared with those with a
score of 16–19, an absolute conclusion that there is a drug
effect in patients with mild AD but not those with
moderate AD would appear unlikely.
Across many disease states, the clinical meaningfulness
of a therapeutic effect is often judged by the point difference
on a particular scale, usually in the context of an improve-
ment in scores. For a treatment that targets the underlying
pathophysiology of AD, point differences need to be inter-
preted in the context of the duration of treatment necessary
to achieve that difference because the difference in scores
for various outcome measures between active treatment
and placebo might be expected to increase over time.
Consistent with this hypothesis, for both the ADAS-Cog14
and the ADCS-iADL, which are arguably the most relevant
outcome measures for a mild AD population, the
solanezumab-placebo difference appears to increase over
time, without evidence of an attenuation of the effect
through the 18-month course of the trials. Our data (Fig. 2)
suggest that the decline in the placebo group over 18 months
and differences between active treatment and placebo
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study may help to clarify this.
Plasma and CSF biomarker findings in the mild AD study
population were similar to those reported previously
for phase 2 studies and for the phase 3 mild-to-moderate
AD population [9,13]. After solanezumab treatment,
substantial increases in plasma and CSF total (bound plus
unbound) Ab1–40 and Ab1–42 were evident, confirming
target engagement in the periphery and the central nervous
system. Interpretation of changes in CSF free (unbound)
fractions of Ab1–40 and Ab1–42 seen with solanezumab
treatment is complex and appears to be dependent on
treatment duration. In a phase 2 study, 12 weeks of
solanezumab administration produced a small non-
significant, but potentially dose-related decrease in free
(unbound) Ab1–40 relative to placebo [9]. In the two, larger
and longer 80-week phase 3 studies discussed here, solane-
zumab significantly decreased CSF free Ab1–40 concentra-
tions, confirming the phase 2 findings. In contrast,
12 weeks of solanezumab treatment in the phase 2 study
significantly increased CSF free Ab1–42 concentrations rela-
tive to placebo. Interestingly, the solanezumab-associated
increase in CSF free Ab1–42 levels observed after only
12 weeks was no longer evident after 80 weeks of treatment
in these two phase 3 studies; however, the free Ab1–42 find-
ings continued to be different from those for the free Ab1–40
findings after either 12 weeks (phase 2 study) or 80 weeks
(phase 3 studies). Thus, the solanezumab-associated in-
crease in CSF free Ab1–42 concentrations noted after
12 weeks may be transient and dependent on the duration
of solanezumab treatment. It is important to note that
although the CSF free Ab1–42 concentration in the solanezu-
mab treatment group was no longer different from that of
placebo after 80 weeks of treatment, the CSF free Ab1–40
concentration was significantly reduced in the solanezumab
treatment group compared with placebo. The cause of
different solanezumab treatment duration-dependent effects
on CSF free Ab1–40 and Ab1–42 is not known. We hypothe-
size that the transient rise in CSF free Ab1–42 concentration
(at 12 weeks) may reflect solanezumab treatment-related
release of this form of Ab peptide from amyloid plaque.
Because CSF free Ab1–40 showed only a decrease at 12
and 80 weeks, this finding may reflect the considerably
smaller amount of this particular Ab isoform associated
with amyloid plaque. Although EXPEDITION 3 will pro-
vide an opportunity to replicate the 80-week phase 3 findings
reported here, assessment of solanezumab effects on CSF
free Ab1–40 and free Ab1–42 over various treatment durations
will be required to further test this hypothesis.
A numeric reduction was seen in the florbetapir SUVR in
the solanezumab treatment group versus placebo (P . .05).
A substantially greater number of florbetapir PET scans will
be obtained in the EXPEDITION3 trial, providing an oppor-
tunity to confirm or refute an effect of solanezumab treat-
ment on amyloid plaque load.Although plasma and CSF biomarker findings were
consistent with target engagement, other biomarker findings
did not provide evidence of downstream changes in neurode-
generation. Similar to previously reported for the mild-to-
moderate AD population [13], solanezumab did not show
an effect on measures postulated as downstream biomarkers
of neurodegeneration (vMRI and CSF tau and p-tau) in the
mild AD population. Slowing of loss of brain volume has
long been discussed as a potential surrogate biomarker for
putative disease-modifying treatments for AD [25]. Howev-
er, to date, only one study of a treatment targeting amyloid,
AN1792, has shown a statistically significant treatment
effect, in this case greater volume loss [26]. In the phase 3
bapineuzumab studies, among APOE ε4 carriers there was
a numerical increase in the annual rate of loss of brain vol-
ume in the bapineuzumab group (19.9 6 0.50 mL/y) versus
placebo (18.7 6 0.59 mL/y; P 5 .13) but no difference was
observed between treatment groups among noncarriers [5].
Thus, as even the desired direction of change for vMRI in
studies of treatments targeting amyloid is in question, the
lack of effect of solanezumab on vMRI is difficult to inter-
pret. CSF tau and p-tau concentrations are widely reported
to be increased in patients with AD. Interestingly, CSF con-
centrations of tau/p-tau are not elevated for patients with
other “tauopathies,” such as frontotemporal dementia and
progressive supranuclear palsy [27–29]. Findings from
phase 3 studies of bapineuzumab did show a small but
statistically significant decrease in p-tau in APOE ε4
carriers; no effect on these biomarkers was seen in the
APOE ε4 noncarriers [5]. Thus, in the bapineuzumab trials,
small decreases in brain volume and decreases in concentra-
tion of CSF tau were observed in actively treated APOE ε4
carriers but with a lack of effect on clinical scores;
conversely, in the EXPEDITION studies, no drug effect
was seen on brain volumes or CSF tau, but a separation in
clinical scores was observed in these secondary analyses
of the pooled data set. The relationship between concentra-
tions of tau in CSF and in brain may be complex. In the
EXPEDITION3 study and other trials, the use of tau PET im-
aging in addition to determination of CSF concentrations of
tau may provide further insights into the relationship
between tau concentrations in CSF and brain.
The safety of solanezumab in patients with mild AD was
similar to that reported previously for the mild-to-moderate
AD population [13]. ARIA-H and ARIA-E, often associated
with anti-amyloid therapies [5,30,31], were numerically
increased with solanezumab treatment (P . .05 vs.
placebo) in the mild-to-moderate AD population [13] and
in the mild AD population examined here. In the completed
EXPEDITION studies, the ARIA-E incidence was approxi-
mately 1%, and was not clearly related to symptoms or
significantly different from that in the placebo group
(P. .05). In addition, there were no treatment group differ-
ences in either frequency or degree of ARIA-H changes. The
frequency of potential infusion-related AEs and treatment-
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treatment groups.
There are clear limitations to these analyses. Although
analyses of EXPEDITION and EXPEDITION2 pooled data-
set were planned before completion of both trials, the ana-
lyses reported here are based on secondary outcomes of
the studies. To be eligible for study participation, patients
were not required to be amyloid positive at baseline based
on either PET or CSF analysis. Based on florbetapir PET
scans or CSF measures performed in study addenda, approx-
imately 25% of this mild AD study population probably did
not have amyloid at baseline and thus would not likely meet
pathologic criteria for AD; whether these findings are gener-
alizable to the overall mild AD study population is not
known.
In summary, based on these secondary analysis findings,
subjects with mild AD treated with solanezumab in EXPE-
DITION/EXPEDITION2 may have had a slowing in cogni-
tive decline of approximately 34% (as measured using
ADAS-Cog14 and MMSE) and a slowing in functional
decline of approximately 18% (as measured using the
ADCS-iADL). Most subjects in this mild AD population
were taking concomitant standard of care treatment; thus,
the possible effect of solanezumab seen here is in addition
to the effect of currently available symptomatic treatments.
Interestingly, in a recent study by Dysken et al. [32] investi-
gating the effect of vitamin E and memantine in veterans
with mild-to-moderate AD who were already taking a
cholinesterase inhibitor, those given vitamin E alone had a
19% slowing in decline on the full ADCS-ADL; vitamin E
had no statistically significant effects on either the ADAS-
cog orMMSE. The slowing in functional decline was similar
to that which we observed. Discrepancies in the effect on
cognitivemeasures will likely be a subject of future research.
The findings presented here are the first to describe the
possible benefits and risks of solanezumab based on second-
ary analyses of data from patients with mild AD who partic-
ipated in EXPEDITION or EXPEDITION2. Based on these
findings, a third phase 3 study, EXPEDITION3, has been
initiated [2]. Enrolling only patients with mild AD and
with evidence of amyloid pathology, EXPEDITION3 will
continue to explore the possible effects of solanezumab in
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1. Systematic review: Although phase 3 studies of
solanezumab in a mild-to-moderate Alzheimer’s
disease (AD) population (EXPEDITION/EXPEDI-
TION2) did not meet their primary endpoints (Doody
et al. [2]), planned subgroup analyses in the mild AD
population showed slowing in cognitive (Alz-
heimer’s Disease Assessment Scale Cognitive sub-
scale, Mini-Mental State Examination), and
functional (instrumental items of the ADCS-ADLs)
decline with solanezumab versus placebo. These
findings, in combination with an acceptable safety
profile, were sufficient to warrant initiation of a third
phase 3 trial in a mild AD population (EXPEDI-
TION3; Karran et al. [2]).
2. Interpretation: This article is the first to provide effi-
cacy, safety, and biomarker results from these
planned subgroup analyses in the mild AD popula-
tion. These results support the amyloid hypothesis
of AD pathogenesis and are consistent with an
emerging consensus that potential therapies targeting
amyloid bmay bemore effectivewhen used earlier in
the disease course.
3. Future directions: Results from EXPEDITION3 may
support the findings from these secondary analyses
of EXPEDITION/EXPEDITION2.References
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